X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
1. H 168 68
2. H 168-68
3. H 16868
4. Magnesium, Omeprazole
5. Omeprazole
6. Omeprazole Magnesium
7. Omeprazole Sodium
8. Prilosec
9. Sodium, Omeprazole
1. Omeprazole Sodium
2. Losec Sodium
3. H 168/68 Sodium
4. 95510-70-6
5. Omeprazole Sodium [usan]
6. 161796-78-7
7. Omeprazole (as Sodium)
8. Kv03yz6qlw
9. 95510-70-6 (sodium)
10. Andra
11. Omeprazole Sodium (usan)
12. 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole, Sodium Salt
13. 1h-benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
14. (s)-omeprazole Sodium
15. Esomeprazole Sodium Salt
16. Sompraz
17. Sodium 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
18. Unii-kv03yz6qlw
19. Losec Sodium (tn)
20. Esomeprazole Sodium (nexium)
21. Omeprazole Sodium [jan]
22. Chembl2105294
23. H-168/68 Sodium
24. Chebi:31934
25. Omeprazole Sodium [mart.]
26. Hms3651e16
27. Omeprazole Sodium [who-dd]
28. Bcp23377
29. Esomeprazole Sodium (nexium I.v.)
30. Ac-403
31. S5658
32. Akos024255604
33. Bcp9000660
34. Omeprazole Sodium [ep Monograph]
35. Bcp0726000228
36. Sw219428-1
37. D01207
38. Ab01274809-01
39. Q27282459
40. Sodium 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-3ah-benzimidazole
1. Omeprazole Sodium Hydrate
| Molecular Weight | 367.4 g/mol |
|---|---|
| Molecular Formula | C17H18N3NaO3S |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | 367.09665690 g/mol |
| Monoisotopic Mass | 367.09665690 g/mol |
| Topological Polar Surface Area | 81.5 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 459 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Esomeprazole sodium |
| Drug Label | The active ingredient in esomeprazole sodium for injection is (S)-5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole sodium, a proton pump inhibitor that inhibits gastric acid secretion. Esomeprazole is the S-isome... |
| Active Ingredient | Esomeprazole sodium |
| Dosage Form | Injectable |
| Route | Intravenous |
| Strength | eq 20mg base/vial; eq 40mg base/vial |
| Market Status | Prescription |
| Company | Sun Pharma Global |
| 2 of 4 | |
|---|---|
| Drug Name | Nexium |
| PubMed Health | Esomeprazole |
| Drug Classes | Gastric Acid Secretion Inhibitor, Gastrointestinal Agent |
| Drug Label | The active ingredient in NEXIUM (esomeprazole magnesium) Delayed-Release Capsules and NEXIUM (esomeprazole magnesium) For Delayed-Release Oral Suspension is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole... |
| Active Ingredient | Esomeprazole magnesium |
| Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
| Route | Oral |
| Strength | eq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet |
| Market Status | Prescription |
| Company | Astrazeneca |
| 3 of 4 | |
|---|---|
| Drug Name | Esomeprazole sodium |
| Drug Label | The active ingredient in esomeprazole sodium for injection is (S)-5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole sodium, a proton pump inhibitor that inhibits gastric acid secretion. Esomeprazole is the S-isome... |
| Active Ingredient | Esomeprazole sodium |
| Dosage Form | Injectable |
| Route | Intravenous |
| Strength | eq 20mg base/vial; eq 40mg base/vial |
| Market Status | Prescription |
| Company | Sun Pharma Global |
| 4 of 4 | |
|---|---|
| Drug Name | Nexium |
| PubMed Health | Esomeprazole |
| Drug Classes | Gastric Acid Secretion Inhibitor, Gastrointestinal Agent |
| Drug Label | The active ingredient in NEXIUM (esomeprazole magnesium) Delayed-Release Capsules and NEXIUM (esomeprazole magnesium) For Delayed-Release Oral Suspension is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole... |
| Active Ingredient | Esomeprazole magnesium |
| Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
| Route | Oral |
| Strength | eq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet |
| Market Status | Prescription |
| Company | Astrazeneca |
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
Market Place
